HLS Therapeutics Inc. (TSX:HLS)
Canada · Delayed Price · Currency is CAD 3.700
+0.100 (2.78%)
Sep 4, 2026, 4:00 PM EST
HLS Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, HLS Therapeutics stock has a consensus rating of "Buy" and an average price target of $7.32. The average 1-year stock price forecast is 97.84% higher than the current stock price, while the lowest is $4.42 (+19.46%) and the highest is $11.94 (+222.70%).
Price Target: $7.32 (+97.84%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for HLS Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Feb '26 | Mar '26 | May '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 2 | 1 | 1 | 1 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $4.45 | Hold | Maintains | $4.45 | +20.27% | Aug 14, 2026 |
| Bloom Burton | Bloom Burton | Buy Maintains $12.00 | Buy | Maintains | $12.00 | +224.32% | Aug 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold Initiates $5.00 | Hold | Initiates | $5.00 | +35.14% | May 19, 2026 |
Financial Forecast
Revenue This Year
58.44M
from 55.50M
Increased by 5.29%
Revenue Next Year
65.03M
from 58.44M
Increased by 11.27%
EPS This Year
-0.21
from -0.39
EPS Next Year
0.02
from -0.21
EPS and Forward PE are based on non-GAAP adjusted numbers.